Healio

First patient dosed in Melt’s phase 3 program of needle- and opioid-free cataract sedation

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. MELT-300 is a combination of midazolam and ketamine ...
Business Wire

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an ...
Business Wire

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first ...
The New England Journal of Medicine

Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis

In a multicenter, double-blind trial, we randomly assigned mechanically ventilated adults with sepsis to receive dexmedetomidine (0.2 to 1.5 μg per kilogram of body weight per hour) or propofol (5 to ...